SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 542.98 |
Enterprise Value ($M) | 474.54 |
Book Value ($M) | 269.37 |
Book Value / Share | 8.48 |
Price / Book | 2.02 |
NCAV ($M) | 172.69 |
NCAV / Share | 5.44 |
Price / NCAV | 3.14 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.07 |
Return on Assets (ROA) | 0.05 |
Return on Equity (ROE) | 0.11 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.38 |
Current Ratio | 2.38 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 414.17 |
Assets | 510.84 |
Liabilities | 241.48 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 129.01 |
Operating Income | -3.16 |
Net Income | -6.68 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 139.80 |
Cash from Investing | -138.40 |
Cash from Financing | 21.04 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Baker Bros. Advisors Lp | 13.20 | 3.43 | |
13G/A | Price T Rowe Associates Inc /md/ | 9.00 | -0.16 | |
13G/A | Roche Finance Ltd | 8.20 | -2.47 | |
13G/A | Redmile Group, LLC | 3.80 | -30.76 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
7,232 | 63,848 | 11.33 | |
26,336 | 109,430 | 24.07 | |
12,339 | 119,092 | 10.36 | |
31,505 | 290,452 | 10.85 | |
11,270 | 68,474 | 16.46 | |
(click for more detail) |
Similar Companies | |
---|---|
TKNO – Alpha Teknova, Inc. | TLPH – Talphera, Inc. |
TNGX – Tango Therapeutics, Inc. | TRVI – Trevi Therapeutics, Inc. |
TSBX – Turnstone Biologics Corp. |
Financial data and stock pages provided by
Fintel.io